Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for Seattle Genetics Inc�
36.25
-0.18 (-0.49%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.73 - 37.88
52 week 30.05 - 55.99
Open 36.76
Vol / Avg. 1.22M/1.16M
Mkt cap 4.49B
P/E     -
Div/yield     -
EPS -0.62
Shares 123.88M
Beta 1.36
Inst. own 104%
May 11, 2015
Seattle Genetics Annual Shareholder Meeting (Estimated) Add to calendar
Apr 29, 2015
Q1 2015 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
Seattle Genetics Inc at Barclays Healthcare Conference - 8:30AM EDT - Add to calendar
Mar 4, 2015
Seattle Genetics Inc at Cowen Health Care Conference - 9:20AM EST - Add to calendar
Feb 12, 2015
Seattle Genetics Inc at Leerink Global Healthcare Conference
Feb 10, 2015
Q4 2014 Seattle Genetics Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Seattle Genetics Inc Earnings Release
Jan 12, 2015
Seattle Genetics Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -35.90% -26.55%
Operating margin -37.30% -26.98%
EBITD margin - -26.98%
Return on average assets -22.84% -16.15%
Return on average equity -49.09% -34.53%
Employees 582 -
CDP Score - -

Address

21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Christopher S. Boerner Ph.D. Executive Vice President - Commercial
Age: 43
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 52
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Executive Vice President - Technical Operations, Process Sciences
Age: 53
Bio & Compensation  - Reuters
Charles R. Romp Senior Vice President - Sales
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 45
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 49
Bio & Compensation  - Reuters